WO2000035488A2 - Medicaments antagonistes du recepteur de la vitronectine - Google Patents

Medicaments antagonistes du recepteur de la vitronectine Download PDF

Info

Publication number
WO2000035488A2
WO2000035488A2 PCT/US1999/030312 US9930312W WO0035488A2 WO 2000035488 A2 WO2000035488 A2 WO 2000035488A2 US 9930312 W US9930312 W US 9930312W WO 0035488 A2 WO0035488 A2 WO 0035488A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituted
aryl
amino
group
Prior art date
Application number
PCT/US1999/030312
Other languages
English (en)
Other versions
WO2000035488A3 (fr
Inventor
Milind Rajopadhye
Thomas David Harris
Edward H. Cheesman
Original Assignee
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharmaceuticals Company filed Critical Du Pont Pharmaceuticals Company
Priority to SI9930981T priority Critical patent/SI1140203T1/sl
Priority to DK99967442T priority patent/DK1140203T3/da
Priority to DE69936148T priority patent/DE69936148T2/de
Priority to EP99967442A priority patent/EP1140203B1/fr
Priority to CA002346935A priority patent/CA2346935A1/fr
Priority to AU23715/00A priority patent/AU2371500A/en
Publication of WO2000035488A2 publication Critical patent/WO2000035488A2/fr
Publication of WO2000035488A3 publication Critical patent/WO2000035488A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4806—Details not adapted to a particular type of sample
    • G01N25/4813—Details not adapted to a particular type of sample concerning the measuring means
    • G01N25/482—Details not adapted to a particular type of sample concerning the measuring means concerning the temperature responsive elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00279—Features relating to reactor vessels
    • B01J2219/00306—Reactor vessels in a multiple arrangement
    • B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
    • B01J2219/00315—Microtiter plates
    • B01J2219/00317—Microwell devices, i.e. having large numbers of wells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00495—Means for heating or cooling the reaction vessels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00702—Processes involving means for analysing and characterising the products
    • B01J2219/00707—Processes involving means for analysing and characterising the products separated from the reactor apparatus
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule : (Q)d-Ln-Ch, utiles pour le diagnostic et le traitement du cancer, ainsi que des méthodes d'imagerie de tumeurs et des méthodes de traitement du cancer chez un patient ; de nouveaux composés utiles pour la surveillance du traitement de l'angiogenèse et la destruction de nouveaux vaisseaux formés par angiogenèse ; de nouveaux composés utiles à l'imagerie de l'athérosclérose, de la resténose, de l'ischémie cardiaque et des troubles du myocarde dus à la reperfusion ; et de nouveaux composés convenant au traitement de la polyarthrite rhumatoïde. Ces médicaments sont constitués d'un groupe fonctionnel de ciblage se liant à un récepteur régulé positivement pendant l'angiogenèse, éventuellement d'un groupe de liaison, et d'un radio-isotope efficace au plan thérapeutique ou d'un groupe fonctionnel pouvant être utilisé à des fins diagnostiques. Ce groupe fonctionnel est un radio-isotope émettant des rayons gamma ou des positrons, un agent de contraste pour imagerie par résonance magnétique, un agent de contraste opaque aux rayons X, ou un agent de contraste opaque aux ultrasons.
PCT/US1999/030312 1998-12-18 1999-12-17 Medicaments antagonistes du recepteur de la vitronectine WO2000035488A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SI9930981T SI1140203T1 (sl) 1998-12-18 1999-12-17 Viktronektin receptor farmacevtski antagonist
DK99967442T DK1140203T3 (da) 1998-12-18 1999-12-17 Farmaceutiske præparater som vitronectinreceptorantagonist
DE69936148T DE69936148T2 (de) 1998-12-18 1999-12-17 Vitronektinrezeptorantagonist-arzneimittel
EP99967442A EP1140203B1 (fr) 1998-12-18 1999-12-17 Medicaments antagonistes du recepteur de la vitronectine
CA002346935A CA2346935A1 (fr) 1998-12-18 1999-12-17 Medicaments antagonistes du recepteur de la vitronectine
AU23715/00A AU2371500A (en) 1998-12-18 1999-12-17 Vitronectin receptor antagonist pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11282998P 1998-12-18 1998-12-18
US60/112,829 1998-12-18

Publications (2)

Publication Number Publication Date
WO2000035488A2 true WO2000035488A2 (fr) 2000-06-22
WO2000035488A3 WO2000035488A3 (fr) 2000-11-09

Family

ID=22346047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030312 WO2000035488A2 (fr) 1998-12-18 1999-12-17 Medicaments antagonistes du recepteur de la vitronectine

Country Status (10)

Country Link
EP (1) EP1140203B1 (fr)
AT (1) ATE362772T1 (fr)
AU (1) AU2371500A (fr)
CA (1) CA2346935A1 (fr)
DE (1) DE69936148T2 (fr)
DK (1) DK1140203T3 (fr)
ES (1) ES2288040T3 (fr)
PT (1) PT1140203E (fr)
TR (1) TR200101775T2 (fr)
WO (1) WO2000035488A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098294A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
WO2002059088A1 (fr) * 2001-01-23 2002-08-01 Wyeth Derives de 1-aryl-ou 1-alkylsulfonylbenzazole utilises en tant que ligands de 5-hydroxytryptamine-6
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2004100996A1 (fr) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Composes de l'antagoniste du recepteur de la vitronectine et leur utilisation dans la preparation de produits radio pharmaceutiques
WO2004081574A3 (fr) * 2003-03-10 2004-12-16 Univ Open Detection, surveillance et traitement du cancer
WO2005009963A1 (fr) * 2003-06-13 2005-02-03 Bristol-Myers Squibb Pharma Company Chelateurs et produits radiopharmaceutiques de complexes metalliques macrocycliques associes
US7255875B2 (en) 2002-01-24 2007-08-14 Barnes-Jewish Hospital Integrin targeted imaging agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US20080095704A1 (en) * 2004-07-02 2008-04-24 Alan Cuthbertson Imaging Agents with Improved Pharmacokinetic Profiles
US7504088B2 (en) 2004-06-09 2009-03-17 Kereos, Inc. Lipophilic derivatives of chelate monoamides
US7879881B2 (en) 2002-08-16 2011-02-01 Janssen Pharmaceutica Nv Piperidinyl compounds that selectively bind integrins
WO2015046278A1 (fr) * 2013-09-24 2015-04-02 富士フイルム株式会社 Nouveau composé contenant de l'azote ou son sel, ou son complexe métallique
JP2016183151A (ja) * 2015-03-25 2016-10-20 富士フイルム株式会社 インテグリンが関与する疾患の診断または治療の処置剤
CN107428755A (zh) * 2015-03-25 2017-12-01 富士胶片株式会社 新型的含氮化合物或其盐的制造方法以及它们的制造中间体

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine
WO1996041803A1 (fr) * 1995-06-13 1996-12-27 Glaxo Group Limited Derives d'acide piperidineacetique comme inhibiteurs d'agregat de plaquettes sanguines dependant du fibrinogene
WO1997008145A1 (fr) * 1995-08-30 1997-03-06 G.D. Searle & Co. Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine
WO1997023480A1 (fr) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Nouveaux antagonistes de recepteurs d'integrines
WO1998014220A2 (fr) * 1996-10-02 1998-04-09 Du Pont Pharmaceuticals Company PEPTIDES CYCLIQUES CONTENANT DES AGENTS CHELATANTS ET MARQUES AU TECHNETIUM 99 m
WO1998016256A1 (fr) * 1996-10-16 1998-04-23 The Burnham Institute Imagerie par resonance magnetique utilisee detecter un thrombus
WO1999006049A1 (fr) * 1997-08-04 1999-02-11 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine
US6040311A (en) * 1998-07-29 2000-03-21 Merck & Co., Inc. Integrin receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine
WO1996041803A1 (fr) * 1995-06-13 1996-12-27 Glaxo Group Limited Derives d'acide piperidineacetique comme inhibiteurs d'agregat de plaquettes sanguines dependant du fibrinogene
WO1997008145A1 (fr) * 1995-08-30 1997-03-06 G.D. Searle & Co. Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine
WO1997023480A1 (fr) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Nouveaux antagonistes de recepteurs d'integrines
WO1998014220A2 (fr) * 1996-10-02 1998-04-09 Du Pont Pharmaceuticals Company PEPTIDES CYCLIQUES CONTENANT DES AGENTS CHELATANTS ET MARQUES AU TECHNETIUM 99 m
WO1998016256A1 (fr) * 1996-10-16 1998-04-23 The Burnham Institute Imagerie par resonance magnetique utilisee detecter un thrombus
WO1999006049A1 (fr) * 1997-08-04 1999-02-11 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine
US6040311A (en) * 1998-07-29 2000-03-21 Merck & Co., Inc. Integrin receptor antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BATT, DOUGLAS G. ET AL: "Disubstituted indazoles as potent alphavbeta3 integrin antagonists." ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (1998) VOL. 216, NO. 1-3, PP. MEDI 66. MEETING INFO.: 216TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY BOSTON, MASSACHUSETTS, USA AUGUST 23-27, 1998 AMERICAN CHEMICAL SOCIETY. , XP000915237 *
DENARDO S J ET AL: "Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy." CANCER BIOTHER RADIOPHARM, (2000 FEB) 15 (1) 71-9. , XP000925000 *
HORTON: "The avb3 integrin "vitronectin receptor"" INT J. BIOCHEM. CELL. BIOL., vol. 29, no. 5, May 1997 (1997-05), pages 721-725, XP000923470 *
KERR J S ET AL: "Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors." ANTICANCER RESEARCH, (1999 MAR-APR) 19 (2A) 959-68. , XP000924849 *
LIU, SHUANG ET AL: "Technetium Complexes of a Hydrazinonicotinamide-Conjugated Cyclic Peptide and 2-Hydrazinopyridine: Synthesis and Characterization" INORG. CHEM. (1999), 38(6), 1326-1335 , XP000924906 *
VAN WAES C. ET AL: "Effects of the novel av integrin antagonist SM256 and cis-platinum on growth of murine squamous cel carcinoma PAM LY8" INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 16, 2000, pages 1189-1195, XP000925238 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321045B2 (en) 1998-12-18 2008-01-22 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001098294A3 (fr) * 2000-06-21 2003-01-09 Du Pont Pharm Co Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
WO2001098294A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
WO2002059088A1 (fr) * 2001-01-23 2002-08-01 Wyeth Derives de 1-aryl-ou 1-alkylsulfonylbenzazole utilises en tant que ligands de 5-hydroxytryptamine-6
US7727512B2 (en) 2002-01-24 2010-06-01 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7344698B2 (en) 2002-01-24 2008-03-18 Barnes-Jewish Hospital Integrin targeted imaging agents
EP2269659A1 (fr) 2002-01-24 2011-01-05 Barnes Jewish Hospital Agents de contraste ciblant une intégrine
US7255875B2 (en) 2002-01-24 2007-08-14 Barnes-Jewish Hospital Integrin targeted imaging agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7566442B2 (en) 2002-01-24 2009-07-28 Barnes-Jewish Hospital Integrin targeted imaging agents
US7879881B2 (en) 2002-08-16 2011-02-01 Janssen Pharmaceutica Nv Piperidinyl compounds that selectively bind integrins
US8110683B2 (en) 2002-08-16 2012-02-07 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
WO2004081574A3 (fr) * 2003-03-10 2004-12-16 Univ Open Detection, surveillance et traitement du cancer
EP1806585A1 (fr) 2003-03-10 2007-07-11 The Open University Détection, surveillance et traitement du cancer
WO2004100996A1 (fr) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Composes de l'antagoniste du recepteur de la vitronectine et leur utilisation dans la preparation de produits radio pharmaceutiques
WO2005009963A1 (fr) * 2003-06-13 2005-02-03 Bristol-Myers Squibb Pharma Company Chelateurs et produits radiopharmaceutiques de complexes metalliques macrocycliques associes
US7319149B2 (en) 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7504088B2 (en) 2004-06-09 2009-03-17 Kereos, Inc. Lipophilic derivatives of chelate monoamides
US20140286866A1 (en) * 2004-07-02 2014-09-25 Ge Healthcare As Imaging agents with improved pharmacokinetic profiles
US20080095704A1 (en) * 2004-07-02 2008-04-24 Alan Cuthbertson Imaging Agents with Improved Pharmacokinetic Profiles
EP3929196A1 (fr) * 2013-09-24 2021-12-29 FUJIFILM Corporation Nouveau composé contenant de l'azote ou son sel ou son complexe métallique
WO2015046278A1 (fr) * 2013-09-24 2015-04-02 富士フイルム株式会社 Nouveau composé contenant de l'azote ou son sel, ou son complexe métallique
JPWO2015046278A1 (ja) * 2013-09-24 2017-03-09 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
EP4249471A3 (fr) * 2013-09-24 2023-10-18 FUJIFILM Corporation Composition pharmaceutique d'un composé contenant de l'azote ou son sel ou son complexe métallique
JP2018027961A (ja) * 2013-09-24 2018-02-22 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
US11426473B2 (en) 2013-09-24 2022-08-30 Fujifilm Corporation Nitrogen-containing compound or salt thereof, or metal complex thereof
JP2016183151A (ja) * 2015-03-25 2016-10-20 富士フイルム株式会社 インテグリンが関与する疾患の診断または治療の処置剤
CN111171026A (zh) * 2015-03-25 2020-05-19 富士胶片株式会社 含氮化合物或其盐的制造中间体
CN107428755B (zh) * 2015-03-25 2020-03-03 富士胶片株式会社 含氮化合物或其盐的制造方法以及它们的制造中间体
CN111171026B (zh) * 2015-03-25 2023-03-03 富士胶片株式会社 含氮化合物或其盐的制造中间体
CN107428755A (zh) * 2015-03-25 2017-12-01 富士胶片株式会社 新型的含氮化合物或其盐的制造方法以及它们的制造中间体

Also Published As

Publication number Publication date
EP1140203B1 (fr) 2007-05-23
AU2371500A (en) 2000-07-03
ATE362772T1 (de) 2007-06-15
PT1140203E (pt) 2007-08-30
ES2288040T3 (es) 2007-12-16
DE69936148D1 (de) 2007-07-05
DE69936148T2 (de) 2008-01-24
EP1140203A2 (fr) 2001-10-10
DK1140203T3 (da) 2007-09-10
TR200101775T2 (tr) 2002-07-22
WO2000035488A3 (fr) 2000-11-09
CA2346935A1 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
US6322770B1 (en) Indazole vitronectin receptor antagonist pharmaceuticals
US6683163B2 (en) Vitronectin receptor antagonist pharmaceuticals
EP1296678A2 (fr) Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
AU2001270025A1 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US6524553B2 (en) Quinolone vitronectin receptor antagonist pharmaceuticals
US6558649B1 (en) Vitronectin receptor antagonist pharmaceuticals
US6838074B2 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
EP1140203B1 (fr) Medicaments antagonistes du recepteur de la vitronectine
US6548663B1 (en) Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) Vitronectin receptor antagonist pharmaceuticals
EP1423152A2 (fr) Imagerie simultanee de perfusion cardiaque et agent d'imagerie cible sur le recepteur de la vitronectine
AU2002331042A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6794518B1 (en) Vitronectin receptor antagonist pharmaceuticals
MXPA01006151A (en) Vitronectin receptor antagonist pharmaceuticals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BR CA CN CZ EE HU IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BR CA CN CZ EE HU IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2346935

Country of ref document: CA

Ref document number: 2346935

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999967442

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/01775

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999967442

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999967442

Country of ref document: EP